[4CMenB vaccine for primary vaccination]
Perelli L, García Martí S, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A.
            Record ID 32018001539
            Spanish
                        
                Original Title:
                Vacuna 4CMenB en inmunización primaria
            
                                                            
                Authors' recommendations:
                Moderate quality evidence suggests that primary vaccination with 4CMenB meningococcal vaccine achieves a reduction in the cases of severe infection by Neisseria Meningitidis serogroup B. Given its low incidence, at population level, this benefit is reduced. This vaccine has an adequate safety profile. In Argentina the serogroup B currently accounts for half of Neisseria Meningitidis infections. 
Most of the economic assessments carried out in high-income countries show that universal primary vaccination with 4CMenB was not cost-effective. 
Some high-income countries could include it in their vaccination schedule after reaching price agreements with the manufacturers. There is a discrepancy among high-income countries regarding universal primary vaccination coverage with 4CMenB. None of the countries in the region cover universal primary vaccination with this vaccine. Most of the public and private health funders from high-income countries agree that patients at high risk of Neisseria Meningitidis infection need to be vaccinated.
Some scientific societies suggest the potential benefit of primary vaccination with 4CMenB and they all agree on it benefits for high-risk groups.
            
                                    
            Details
                        
                Project Status:
                Completed
            
                                                            
                Year Published:
                2019
            
                                    
                URL for published report:
                https://www.iecs.org.ar/home-ets/
            
                                                            
                English language abstract:
                An English language summary is available
            
                                    
                Publication Type:
                Not Assigned
            
                                    
                Country:
                Argentina
            
                                                
                        MeSH Terms
            - Meningitis, Bacterial
 - Meningitis, Meningococcal
 - Meningococcal Vaccines
 - Vaccination
 - Child Health
 - Infant
 
Contact
                        
                Organisation Name:
                Institute for Clinical Effectiveness and Health Policy
            
            
                        
                Contact Address:
                Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
            
                                    
                Contact Name:
                info@iecs.org.ar
            
                                    
                Contact Email:
                info@iecs.org.ar
            
                                    
                Copyright:
                Institute for Clinical Effectiveness and Health Policy (IECS)
            
                    
                This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.